Three IPOs raised $363 million in the past week. The two biotechs and a Chinese school operator popped an average of 21%, helping raise the year-to-date average to 8.3%. Just one company joined the calendar, micro-cap gunshot detector ...read more
G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, raised $105 million by offering 7 million shares at $15, the low end of the range of $15 to $17. G1 originally planned to offer 6.25 million shares at the same range. At the...read more
There are four deals on the calendar for the week ahead.
Chinese international school operator Bright Scholar Education is leading the week with a $135 million offering. Three biotechs are also expected to price deals, raising a total of $177 million.
...read more
G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, announced terms for its IPO on Monday.
The Research Triangle Park, NC-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17...read more
US IPO Weekly Recap: 3 deals post double-digit returns
Three IPOs raised $363 million in the past week. The two biotechs and a Chinese school operator popped an average of 21%, helping raise the year-to-date average to 8.3%. Just one company joined the calendar, micro-cap gunshot detector ...read more
Cancer biotech G1 Therapeutics prices upsized IPO at $15, the low end of the range
G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, raised $105 million by offering 7 million shares at $15, the low end of the range of $15 to $17. G1 originally planned to offer 6.25 million shares at the same range. At the...read more
US IPO Week Ahead: Chinese international school operator and 3 biotechs
There are four deals on the calendar for the week ahead. Chinese international school operator Bright Scholar Education is leading the week with a $135 million offering. Three biotechs are also expected to price deals, raising a total of $177 million. ...read more
Cancer biotech G1 Therapeutics sets terms for $100 million IPO
G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, announced terms for its IPO on Monday. The Research Triangle Park, NC-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17...read more